Multimorbidity-adjusted pharmacotherapy intensity
1 paper3 findings
- Humans1
Associations
3Hospitalization
upin humans1OR 1.29
1 study
Hospitalization
upin humans1OR 1.29
Multimorbidity-adjusted pharmacotherapy intensity is associated with hospitalization in humans (Q4 versus Q1: OR 1.29).
“Q3 and Q4 also had higher hospitalization odds (OR, 1.24 and 1.29, respectively).”
HumansMultimorbidity; Q4 versus Q1, fully adjusted modelPast-year hospitalization in 2020n = 7,477
Geriatrics & gerontology international1 Oct 2026
Incident ADL disability
upin humans1OR 1.32
1 study
Incident ADL disability
upin humans1OR 1.32
Multimorbidity-adjusted pharmacotherapy intensity is associated with incident ADL disability in humans (Q4 versus Q1: OR 1.32, 95% CI 1.06–1.64).
“For participants without baseline disability, Q4 was significantly associated with incident ADL disability (OR, 1.32; 95% CI, 1.06-1.64).”
HumansMultimorbidity without baseline disability; Q4 versus Q1, fully adjusted model2015–2020
Geriatrics & gerontology international1 Oct 2026
ADL disability
upin humans1OR 1.28
1 study
ADL disability
upin humans1OR 1.28
Multimorbidity-adjusted pharmacotherapy intensity is associated with ADL disability in humans (Q4 versus Q1: OR 1.28, 95% CI 1.07–1.53).
“For any ADL disability, Q3 (OR, 1.21; 95% CI, 1.01-1.44) and Q4 (OR, 1.28; 95% CI, 1.07-1.53) remained significant.”
HumansMultimorbidity; Q4 versus Q1, fully adjusted model2015–2020n = 7,477
Geriatrics & gerontology international1 Oct 2026